UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

Annals of oncology, 2014-12, Vol.25 (12), p.2385-2391

2014

Volltextzugriff (PDF)

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial

Annals of oncology, 2021-04, Vol.32 (4), p.512-521

2021

Volltextzugriff (PDF)

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

Annals of oncology, 2015-09, Vol.26 (9), p.1877-1883

2015

Volltextzugriff (PDF)

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Annals of oncology, 2015-09, Vol.26 (9), p.1883-1889

2015

Volltextzugriff (PDF)

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Annals of oncology, 2018-04, Vol.29 (4), p.945-952

2018

Volltextzugriff (PDF)

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Annals of oncology, 2013-06, Vol.24 (6), p.1615-1622

2013

Volltextzugriff (PDF)

Attributable causes of cancer in China

Annals of oncology, 2012-11, Vol.23 (11), p.2983-2989

2012

Volltextzugriff (PDF)

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

Annals of oncology, 2015-05, Vol.26 (5), p.943-949

2015

Volltextzugriff (PDF)

Reply to ‘Concern on quality-of-life analysis in the OPTIMAL study’ by Couraud et al

Annals of oncology, 2013-08, Vol.24 (8), p.2197-2198

2013

Volltextzugriff (PDF)

Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China

Annals of oncology, 2019-10, Vol.30 (10), p.1630-1637

2019

Volltextzugriff (PDF)

Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia

Annals of oncology, 2003-05, Vol.14 (5), p.752-757

2003

Volltextzugriff (PDF)

Tumor–ratio–metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection—results of a single-institution study of 1343 Chinese patients

Annals of oncology, 2011-09, Vol.22 (9), p.2049-2056

2011

Volltextzugriff (PDF)

Concern on quality-of-life analysis in the OPTIMAL study

Annals of oncology, 2013-08, Vol.24 (8), p.2196-2197

2013

Volltextzugriff (PDF)

1 – 13 von 13

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThin Solid Films

Zeitschrift / SerieAnnals Of Oncology

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(13)

Sprache

Englisch
(13)
Japanisch
(3)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Attributable causes of cancer in China

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

Reply to ‘Concern on quality-of-life analysis in the OPTIMAL study’ by Couraud et al

Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China

Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia

Tumor–ratio–metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection—results of a single-institution study of 1343 Chinese patients

Concern on quality-of-life analysis in the OPTIMAL study

Aktive Filter

Suchergebnisse filtern